A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-20

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules

NCT04675060

Advanced Solid Tumors

UNKNOWN PHASE1

Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects

NCT05344729

Recurrent/Metastatic Breast Cancer

COMPLETED PHASE1

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

NCT00535522

Cancer

COMPLETED PHASE1

Pharmacokinetic Study of Doxorubicin in Children With Cancer

NCT01095926

Wilms Tumor Neuroblastoma Soft Tissue Sarcoma +1 more

COMPLETED PHASE2

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

NCT02552953

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed or Refractory Lymphoma or Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TQ-B3525

Group Type EXPERIMENTAL

TQ-B3525

Intervention Type DRUG

TQ-B3525 p.o. qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQ-B3525

TQ-B3525 p.o. qd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
* ECOG PS≤1
* Adequate blood cell counts, kidney function and liver function
* Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria

* Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
* Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
* Hepatitis B virus patients with active replication (DNA\> 500 cps / mL), hepatitis C

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No